By Chris Wack
InflaRx shares dropped 29%, to $1.92, after the company priced an underwritten public offering of 8.3 million shares at $2 a share, and in lieu of shares to certain investors, pre-funded warrants to buy up to 6.75 million shares.
All ordinary shares and pre-funded warrants in the offering are being sold by the company.
The offering is expected to close Tuesday.
InflaRx has granted the underwriters a 30-day option to buy up to 2.25 million additional shares at the public offering price, less the underwriting discount.
The company intends to use the proceeds from the offering primarily to fund clinical development of its pipeline candidates, including vilobelimab and INF904, and for general corporate purposes.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 14, 2025 12:39 ET (17:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。